Sugi Predict

Sugi Predict / Compounds / SCHEMBL4079743

SCHEMBL4079743

SCHEMBL4079743

OCCOc1ccnc2ccc(Br)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ SLC22A12 Q96S37 6/20 0.44
▸ GAK O14976 1/20 0.42
▸ EPHB6 O15197 1/20 0.42
▸ RIPK2 O43353 1/20 0.42
▸ STK16 O75716 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ ACVR1 Q04771 1/20 0.42
▸ AAK1 Q2M2I8 1/20 0.42
▸ COQ8A Q8NI60 1/20 0.42
▸ NLK Q9UBE8 1/20 0.42
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ MET P08581 1/20 0.41
▸ NCF1 P14598 1/20 0.40
▸ PDGFRB P09619 3/20 0.39
▸ HTT P42858 2/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29214659 0.88 ALK (0.42) LMNAMAPTSLC22A12GAKMET
SCHEMBL12390292 0.83 PDGFRB (0.54) LMNAMAPTSLC22A12GAKEPHB6
SCHEMBL360467 0.83 GAK (0.47) SLC22A12GAKEPHB6RIPK2STK16
SCHEMBL12101561 0.81 HTR1A (0.49) LMNAMAPTSLC22A12METHTT
SCHEMBL14205888 0.81 GAK (0.42) SLC22A12GAKRIPK2COQ8ANLK
SCHEMBL2621790 0.81 PDGFRB (0.50) LMNASLC22A12GAKEPHB6RIPK2
SCHEMBL10283762 0.81 NCF1 (0.43) MAPTSLC22A12GAKEPHB6RIPK2
SCHEMBL2621792 0.81 HTR7 (0.45) LMNASLC22A12GAKEPHB6RIPK2
SCHEMBL22122413 0.80 SLC22A12 (0.42) LMNASLC22A12GAKEPHB6RIPK2
SCHEMBL2621787 0.80 CYP1A2 (0.47) LMNAMAPTSLC22A12GAKEPHB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2995618-B1 [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) 2019-01-09 — — EP disclosed
EP-2995618-B1 [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) 2019-01-09 — — EP disclosed
US-9512121-B2 [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-12-06 — — US disclosed
US-9512121-B2 [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-12-06 — — US disclosed
US-9512121-B2 [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-12-06 — — US disclosed
US-20160122339-A1 [1,2,4] TRIAZOL [4,3-A] PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-05-05 — — US disclosed
US-20160122339-A1 [1,2,4] TRIAZOL [4,3-A] PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-05-05 — — US disclosed
US-20160122339-A1 [1,2,4] TRIAZOL [4,3-A] PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-05-05 — — US disclosed
EP-2995618-A1 [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) 2016-03-16 — — EP disclosed
EP-2995618-A1 [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) 2016-03-16 — — EP disclosed
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
EP-2084162-B1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS INC (US) 2012-09-12 — — EP disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 — — US disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 — — US disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 — — US disclosed
EP-2084162-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-08-05 — — EP disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122339-A1 [1,2,4] TRIAZOL [4,3-A] PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF MET, CYP4F11, WEE1 LMNA 4676/4885MAPT 3694/4885SLC22A12 3191/4885
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS MAP3K20, TTK, PRKACB LMNA 4059/4885MAPT 1886/4885SLC22A12 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.